ATRS receives CRL for Xyosted: https://finance.yahoo.com/news/antares-pharma-receives-complete-response-224917144.html The CRL identified two deficiencies related to clinical data. Based on findings in studies...the FDA is concerned that XYOSTED could cause a clinically meaningful increase in blood pressure. In addition, the letter also raised a concern regarding the occurrence of depression and suicidality.Ouch. The stock is down only 9%/AH because ATRS pre-announced the expected CRL last week (#msg-135361392).